Welcome to our dedicated page for Inmed Pharmaceuticals news (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on Inmed Pharmaceuticals stock.
InMed Pharmaceuticals Inc. (NASDAQ: INM) is a pharmaceutical drug development company that regularly issues news and updates about its proprietary small molecule programs and related corporate activities. The company focuses on drug candidates targeting the CB1/CB2 receptors in three main therapeutic areas: Alzheimer’s disease, ocular conditions and dermatological indications, and it also reports on the commercial operations of its rare cannabinoid subsidiary BayMedica.
News about InMed often covers progress in its lead Alzheimer’s program INM-901, including preclinical data, pharmacokinetic studies in animal models and scientific presentations at major conferences such as the Alzheimer’s Association International Conference (AAIC). Releases describe how INM-901 is being evaluated across multiple biological pathways associated with Alzheimer’s disease and summarize findings from long-term studies in established disease models.
Investors and followers of INM can also find updates on INM-089, a proprietary small molecule drug candidate under investigation for dry age-related macular degeneration, including preclinical study results and formulation work for intravitreal delivery. In addition, InMed provides business updates on BayMedica, including sales performance, legislative developments affecting rare, non-intoxicating cannabinoids and the subsidiary’s evaluation of alternative supply chain options to maintain regulatory compliance.
Corporate and capital markets developments are another frequent theme in InMed’s news flow. The company announces private placements, preferred investment option amendments, participation in investor conferences, and changes to its board of directors, as well as the outcomes of its annual general and special meetings of shareholders. For readers tracking INM news, this page offers a centralized view of scientific, commercial, financial and governance announcements directly tied to the company’s disclosed activities.
InMed Pharmaceuticals (NASDAQ: INM) has announced positive results from a long-term (7 months) preclinical Alzheimer's Disease (AD) study of INM-901, confirming previous short-term (3 months) pilot study findings. The study, conducted using the 5xFAD amyloidosis model, showed improvements in cognitive function, memory, and locomotor activity in INM-901-treated AD groups compared to placebo-treated groups.
Key points:
- INM-901-treated AD groups showed positive trends towards behavior similar to untreated disease-free groups
- Statistically significant improvements were achieved in certain behavioral criteria
- Results supported and improved upon prior short-term pilot study outcomes
- Further molecular analyses are ongoing to define mechanisms of action
- Development of chemistry, manufacturing, and controls (CMC) is in progress
- GLP studies are being planned to support an IND submission
InMed Pharmaceuticals (NASDAQ: INM) announced that it will present at the Emerging Growth Conference on June 13, 2024, at 1:45 PM EDT. CEO Eric A. Adams will provide a corporate overview followed by a Q&A session. The presentation will be accessible via live webcast, with an archived version available later on EmergingGrowth.com, Emerging Growth YouTube Channel, and InMed's investor relations page.
InMed Pharmaceuticals (NASDAQ: INM) released its financial results for Q3 fiscal 2024, ending March 31, 2024.
The company reported positive preclinical data for its Alzheimer's disease (INM-901) and dry AMD (INM-089) programs. InMed closed the quarter with $7.9 million in cash.
The BayMedica commercial business earned $3.3 million over nine months, an 83% increase from the previous year. Q3 revenues remained flat at $1.2 million, with BayMedica operating profitably.
The company recorded a net loss of $5.7 million for the quarter, down from $7.6 million the previous year. R&D and patents expenses dropped to $2.6 million from $3.1 million. Cash reserves should cover expenses into Q4 2024.
Notably, Alexandra Mancini, SVP Clinical & Regulatory Affairs, will retire effective June 30, 2024.
FAQ
What is the current stock price of Inmed Pharmaceuticals (INM)?
What is the market cap of Inmed Pharmaceuticals (INM)?
